Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation

Feng Xue, Shaojun Shi, Zhenzhen Zhang, Cheng Xu, Jianxin Zheng, Tian Qin, Zhiyu Qian, Xiaoyu Zhao, Ying Tong, Lei Xia, Qiang Xia*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
14 Downloads (Pure)


Circulating tumor cells (CTCs) serves a primary function in metastasis and recurrence of hepatocellular carcinoma (HCC). In the present study, in order to evaluate the analytical performance and clinical value of the liquid biopsy-based platform, a novel integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization (iFISH®) platform was applied to analyze CTCs in patients with HCC undergoing liver transplantation (LT). In total, 30 patients with HCC undergoing LT and 10 healthy volunteers were enrolled. CTCs in peripheral blood that were obtained from each patient prior to LT and 3 months thereafter were detected using the iFISH® platform, and CellSearch® system was performed for each subject for comparison. Using iFISH® and CellSearch®, the percentage of CTCs in patients with pre-operative HCC were 70.00% and 26.67%, respectively. CTCs counted using iFISH® (iFISH-CTCs) were increased compared with CellSearch® (Cellsearch-CTCs) (P5/7.5 ml, 15 vs. 5.5 months; P
Original languageEnglish
Pages (from-to)5481-5488
Number of pages8
JournalOncology Letters
Issue number4
Publication statusPublished - 1-Apr-2018
Externally publishedYes


  • Circulating tumor cell
  • Hepatocellular carcinoma
  • Liquid biopsy
  • Liver transplantation
  • Recurrence
  • Subtraction enrichment

Cite this